A significant paradigm shift is underway in small-molecule drug discovery, as a pioneering collaboration between Ginkgo Datapoints, Tangible Scientific, and…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…
Read More
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
A significant shift is underway in the landscape of small-molecule drug discovery, as a new collaborative platform seeks to revolutionize…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
For decades, the pharmaceutical industry has grappled with the inherent inefficiencies of drug discovery, a process often likened to searching…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
A significant paradigm shift is underway in the pharmaceutical industry’s approach to small-molecule drug discovery, as a new collaborative platform,…
Read More
Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
A new collaborative platform, ADME-One, has been launched by Ginkgo Datapoints, Tangible Scientific, and Inductive Bio, signaling a significant shift…
Read MoreYOU MAY HAVE MISSED
